News|Videos|April 28, 2026

ACIP Charter Changes Move Focus Away From Prevention and Value of Vaccines

Fact checked by: Justin Mancini

Robert H. Hopkins Jr, MD, medical director of the National Foundation for Infectious Diseases, offers commentary about what changing the vaccine committee’s charter means from a functional standpoint and how it affects public health by moving away from vaccines as a prevention strategy.

This is part of a short series with leaders of medical professional organizations to gain insights about the revised Advisory Committee on Immunization Practices (ACIP) charter as well as commentary about the federal government’s suppression of COVID-19 vaccine data.

Earlier this month, the Centers for Disease Control and Prevention published a significantly revised ACIP charter. In effect, this action changes how the committee operates and provides greater power to the current administration.

In opposition to this, the National Foundation for Infectious Diseases (NFID) was one of more than 130 organizations that issued a statement opposing the charter change.

In part, the statement read: “The 130+ undersigned medical, nursing, public health, and patient advocacy groups express our deep concern about the revised charter for the Advisory Committee on Immunization Practices (ACIP) published on April 9. The new charter substantively changes the focus of the committee and its membership structure, which could undermine confidence in vaccines and ultimately affect access to immunizations.

ACIP was established to provide evidence-based guidance on the use of immunizations to prevent diseases, but the revised charter paves the way for an unqualified committee to promote misleading narratives about vaccine safety. For decades, the committee held transparent discussions about vaccines based on patterns of disease, clinical trial and real-world data on efficacy and safety, and cost and implementation considerations. The new charter downplays the value of immunizations for both communities and individuals.”1

To read the entire statement, interested parties can go here.

The NFID serves as a liaison during the ACIP meetings, so it understands intimately how the committee operates. Robert H. Hopkins Jr, MD, medical director of the NFID, says if the charter were to change, it would completely overhaul what it has done traditionally.

“This new charter changes the focus of the committee from one that evaluates new vaccines, reviews vaccines as preventable disease epidemiology, [and] talks about disease and safe implementation of vaccines to protect the American public…to what seems to be one focused on minimizing vaccine confidence and the public's perception of value,” Hopkins said. “In addition, it adds liaison representatives from several organizations that have a long track record of sharing misinformation…. The traditional role of liaisons has been to offer clinical and scientific expertise in real-world settings, not to undermine confidence.”

Timeline: Federal Government vs Professional Medical Organizations

July 2025: The AAP, ACP, and other medical professional organizations file a lawsuit against Kennedy.

March 2026: A federal judge strikes down the current administration's vaccine policies.

April 2026: The CDC significantly revises the ACIP charter. More than 130 organizations take part in releasing a statement condemning the revised charter.

From a philosophical standpoint, the ACIP has operated in a nonpolitical, nonideological way. Hopkins says this shift away from how vaccines prevent diseases to looking at them only from a safety standpoint is a marked departure that leaves short the committee’s work.

“If you read this new proposed charter, there is nothing in there about disease epidemiology, there's nothing in there about effectiveness of vaccines, there's nothing in there about vaccine prevention. It's all focused on safety or lack thereof and on changes in the representation of the liaisons,” Hopkins said. “If you change the focus from looking at the broad picture of the diseases that we can prevent with vaccines and you don't talk about value of vaccines, you're missing at least half of the puzzle.”

In the next episode of the series, Hopkins discusses what we know about COVID-19 vaccines in 2026.

Reference
1. More than 130 organizations express alarm over proposed changes to CDC’s Advisory Committee on Immunization Practices charter. Press release. American College of Physicians. April 28, 2026. Accessed April 28, 2026. https://www.acponline.org/acp-newsroom/more-than-130-organizations-express-alarm-over-proposed-changes-to-cdcs-advisory-committee-on

Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
FAQ: Ebola Prevention, Treatment and the Chances of a US Outbreak
As the Bundibugyo virus outbreak in the Democratic Republic of the Congo surpasses 9300 confirmed cases and 4400 deaths, this FAQ explains how the virus spreads, how it presents, why it is hard to diagnose and treat, which vaccines and therapies are being tested, and why CDC considers the risk to the United States low.